Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis [0.03%]
表皮生长因子受体突变型晚期非小细胞肺癌酪氨酸激酶抑制剂疗效和安全性的网状Meta分析
Abdullah Alanazi,Ismaeel Yunusa,Khaled Elenizi et al.
Abdullah Alanazi et al.
Aim: To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive EGFR mutation. ...
Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform [0.03%]
ROS1阳性非小细胞肺癌的疾病负担和治疗现状：全球患者调查结果摘要
Huamao M Lin,Xiaoyun Pan,Alyssa Biller et al.
Huamao M Lin et al.
Aim: Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing th...
Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer [0.03%]
转移性非小细胞肺癌二线尼伏单抗治疗反应的计算机断层纹理分析
Rahul Ladwa,Kate E Roberts,Connor O&#x;Leary et al.
Rahul Ladwa et al.
Objectives: Assess computed tomography texture analysis of patients likely to benefit from nivolumab. Materials & methods: Texture anal...
Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer [0.03%]
使用尼伏鲁单抗治疗的复发性非小细胞肺癌患者的中性粒细胞/淋巴细胞比率的预后意义
Bernardo L Rapoport,Annette J Theron,Daniel A Vorobiof et al.
Bernardo L Rapoport et al.
Aim: We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. ...
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver [0.03%]
选择最佳的一线治疗方案：没有可用药的致癌驱动因素的非小细胞肺癌
So Yeon Kim,Balazs Halmos
So Yeon Kim
Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. ...
Understanding sex disparities in lung cancer incidence: are women more at risk? [0.03%]
理解肺癌发病率的性别差异：女性风险更大？
Meera V Ragavan,Manali I Patel
Meera V Ragavan
Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung [0.03%]
立体定位消融体放射治疗与常规分次放射治疗早期大细胞神经内分泌肺癌的比较
Rodney E Wegner,Stephen Abel,Athanasios Colonias
Rodney E Wegner
Aim: Some patients with early stage large cell neuroendocrine carcinoma (LCNEC) of the lung are not surgical candidates and will be managed with radiotherapy. We used the national cancer database to identify predictors of...
Lung cancer management challenges amidst COVID-19 pandemic: hope lives here [0.03%]
COVID-19大流行期间肺癌管理挑战：希望在此生根
Abhishek Shankar,Deepak Saini,Ruchir Bhandari et al.
Abhishek Shankar et al.
Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer [0.03%]
肺癌患者接受免疫检查点抑制剂治疗与术前营养状况的关系
Chung-Shien Lee,Craig E Devoe,Xinhua Zhu et al.
Chung-Shien Lee et al.
Background: Checkpoint inhibitors are integral to non-small-cell lung cancer treatment. Existing data suggests that nutritional status may play a role in antitumor immunity. ...
Identification of nine key genes by bioinformatics analysis for predicting poor prognosis in smoking-induced lung adenocarcinoma [0.03%]
生物信息学分析识别九个关键基因以预测吸烟引起的肺腺癌不良预后
Chuanli Ren,Weixiu Sun,Xu Lian et al.
Chuanli Ren et al.
Aim: To screen and identify key genes related to the development of smoking-induced lung adenocarcinoma (LUAD). Materials & methods: We...